Arcus Biosciences Inc (NYSE:RCUS)
$ 16 0.16 (1.01%) Market Cap: 1.46 Bil Enterprise Value: 456.70 Mil PE Ratio: 0 PB Ratio: 2.06 GF Score: 75/100

Arcus Biosciences Inc Domvanalimab Program Update Transcript

Jun 23, 2021 / 09:00PM GMT
Release Date Price: $23.4 (+2.86%)
Operator

Good afternoon, ladies and gentlemen. My name is Loya, and I will be your operator on this call.

(Operator Instructions) Please note that this call is being recorded today, Wednesday, June 23, 2021, at 2:00 p.m. Pacific Time; and will be available on the investors section of Arcus' website at www.arcusbio.com.

I would now like to turn the meeting over to Kaytee Bock, Vice President of Investor Relations and Corporate Strategy from Arcus.

Please go ahead, ma'am.

Katherine Bock
Arcus Biosciences, Inc. - VP of IR & Corporate Strategy

Thank you. Hi, everyone. Thank you, Loya. And thank you all for participating in today's call on such short notice.

Today, we will be discussing this afternoon's announcement regarding the interim analysis from the ARC-7 study. Joining me from Arcus are Terry Rosen, Chief Executive Officer; Juan Jaen, President; Jennifer Jarrett, Chief Operating Officer; Bill Grossman, Chief Medical Officer; and Kartik Krishnan, Senior Vice

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot